INTRODUCTION: Psoriatic arthritis (PsA) affects 10-30% of individuals with psoriasis. Early detection of PsA is crucial to prevent potential irreversible joint damage. The Psoriasis Epidemiology Screening Tool (PEST) has proven to be an effective tool in daily clinical practice, but limited data is available on the analysis of positive responses. Our study aimed to determine the combination of positive responses to individual questions and characterize patients with positive PEST results based on specific anatomical sites of psoriasis, duration of the disease, and epidemiological parameters that could potentially predict PEST positivity. METHODS: The PEST questionnaire was randomly administered to patients with psoriasis without psoriatic arthritis attending the outpatient unit for psoriasis treatment. A total of 351 patients completed the PEST questionnaire over a 24-month period. Patients undergoing various types of therapy were included. Each patient completed the PEST questionnaire once, and epidemiological data (such as age, weight, height, body mass index, smoking status, age of disease onset, disease duration, and family history of psoriasis) were collected, as well as types of therapy. RESULTS: We included 242 men and 109 women with an average age of 49.4 years and duration of psoriasis of 23.3 years. A positive PEST questionnaire result was found in 28.5% of patients; 13.1% had a score of 3, 8.0% a score of 4 and 7.4% a score of 5. Nail psoriasis, higher age, and therapy with biological/targeted therapy were associated with PEST positivity. The most frequently observed positive response was nail involvement. CONCLUSION: The PEST questionnaire is a well-established screening tool for identifying patients at risk of having undiagnosed psoriatic arthritis in daily dermatological practice. Patients with nail involvement, higher age, or treated with modern systemic therapy should be closely monitored, as these factors indicate a higher risk of a positive PEST result and consequently higher risk of having psoriatic arthritis.

Department of Dermatovenereology 3rd Faculty of Medicine Charles University University Hospital Královské Vinohrady Prague Czech Republic

Value Outcomes Prague Czech Republic

See more in PubMed

Ohara Y, Kishimoto M, Takizawa N, et al. Prevalence and clinical characteristics of psoriatic arthritis in Japan. J Rheumatol. 2015;42(8):1439–42. 10.3899/jrheum.141598. PubMed

Kishimoto M, Deshpande GA, Fukuoka K, et al. Clinical features of psoriatic arthritis. Best Pract Res Clin Rheumatol. 2021;35(2):101670. 10.1016/j.berh.2021.101670. PubMed

Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376(10):957–70. 10.1056/NEJMra1505557. PubMed

Alinaghi F, Calov M, Kristensen LE, et al. Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2019;80(1):251-265.e19. 10.1016/j.jaad.2018.06.027. PubMed

Gladman DD. Axial psoriatic arthritis. Curr Rheumatol Rep. 2021;23(6):35. 10.1007/s11926-021-00999-8. PubMed

Pitzalis C. Skin and joint disease in psoriatic arthritis: what is the link? Br J Rheumatol. 1998;37:480–3. 10.1093/rheumatology/37.5.480. PubMed

Haroon M, Gallagher P, FitzGerald O. Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis. Ann Rheum Dis. 2015;74(6):1045–50. 10.1136/annrheumdis-2013-204858. PubMed

Hioki T, Komine M, Ohtsuki M. Diagnosis and intervention in early psoriatic arthritis. J Clin Med. 2022;11(7):2051. 10.3390/jcm11072051. PubMed PMC

Coates LC, Moverley AR, McParland L, et al. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. Lancet. 2015;386(10012):2489–98. 10.1016/S0140-6736(15)00347-5. PubMed PMC

Villani AP, Rouzaud M, Sevrain M, et al. Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: systematic review and meta-analysis. J Am Acad Dermatol. 2015;73(2):242–8. 10.1016/j.jaad.2015.05.001. PubMed

Coates LC, Savage LJ, Chinoy H, et al. Assessment of two screening tools to identify psoriatic arthritis in patients with psoriasis. J Eur Acad Dermatol Venereol. 2018;32(9):1530–4. 10.1111/jdv.14971. PubMed

Mease PJ, Gladman DD, Helliwell P, et al. Comparative performance of psoriatic arthritis screening tools in patients with psoriasis in European/North American dermatology clinics. J Am Acad Dermatol. 2014;71(4):649–55. 10.1016/j.jaad.2014.05.010. PubMed

Ibrahim GH, Buch MH, Lawson C, et al. Evaluation of an existing screening tool for psoriatic arthritis in people with psoriasis and the development of a new instrument: the Psoriasis Epidemiology Screening Tool (PEST) questionnaire. Clin Exp Rheumatol. 2009;27(3):469–74. PubMed

Chang J, Litvinov IV, Ly C, et al. Utilization of the Psoriasis Epidemiology Screening Tool (PEST): a risk stratification strategy for early referral of psoriatic arthritis patients to minimize irreversible erosive joint damage. J Cutan Med Surg. 2022;26(6):600–3. 10.1177/12034754221128796. PubMed PMC

Mease PJ, Palmer JB, Hur P, et al. Utilization of the validated Psoriasis Epidemiology Screening Tool to identify signs and symptoms of psoriatic arthritis among those with psoriasis: a cross-sectional analysis from the US-based Corona Psoriasis Registry. J Eur Acad Dermatol Venereol. 2019;33(5):886–92. 10.1111/jdv.15443. PubMed PMC

Raposo I, Torres T. Nail psoriasis as a predictor of the development of psoriatic arthritis. Actas Dermosifiliogr. 2015;106(6):452–7. 10.1016/j.ad.2015.02.005. PubMed

Zabotti A, De Lucia O, Sakellariou G, et al. Predictors, risk factors, and incidence rates of psoriatic arthritis development in psoriasis patients: a systematic literature review and meta-analysis. Rheumatol Ther. 2021;8(4):1519–34. 10.1007/s40744-021-00378-w. PubMed PMC

Alonso S, Tejón P, Sarasqueta C, et al. Age at disease onset may help to further characterize the disease phenotype in psoriatic arthritis. Joint Bone Spine. 2016;83(5):533–7. 10.1016/j.jbspin.2015.09.004. PubMed

Pouw JN, Jacobs ME, Balak DMW, et al. Do patients with psoriatic arthritis have more severe skin disease than patients with psoriasis only? A systematic review and meta-analysis. Dermatology. 2022;238(6):1108–19. PubMed PMC

Eder L, Haddad A, Rosen CF, et al. The incidence and risk factors for psoriatic arthritis in patients with psoriasis: a prospective cohort study. Arthritis Rheumatol. 2016;68(4):915–23. 10.1002/art.39494. PubMed

Setoyama A, Sawada Y, Saito-Sasaki N, et al. Psoriasis epidemiology screening tool (PEST) is useful for the detection of psoriatic arthritis in the Japanese population. Sci Rep. 2021;11(1):16146. 10.1038/s41598-021-95620-4. PubMed PMC

Gisondi P, Bellinato F, Targher G, et al. Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis. Ann Rheum Dis. 2022;81(1):68–73. 10.1136/annrheumdis-2021-219961. PubMed

Graier T, Salmhofer W, Jonak C, et al. Evolution of characteristics and biologic treatment effectiveness in patients of the Austrian psoriasis registry from 2004–2022. J Dtsch Dermatol Ges. 2023;21(12):1513–23. 10.1111/ddg.15213. PubMed

Kampylafka E, Simon D, d’Oliveira I, et al. Disease interception with interleukin-17 inhibition in high-risk psoriasis patients with subclinical joint inflammation-data from the prospective IVEPSA study. Arthritis Res Ther. 2019;21(1):178. 10.1186/s13075-019-1957-0. PubMed PMC